JUNE 202119give healthcare providers a novel way to test patients quickly and accurately in any location," says Joshi. "Time matters in caring for patients. Understanding the difference between two minutes and 20 minutes, we are developing a product that helps healthcare providers take fast actions to improve patient outcomes and save lives. Our system's ability to test a person right on a soccer field or in an elderly care facility or on the military field is extremely valuable."The company demonstrated the flexibility and scalability of the NanoDx System by rapidly developing the detection of SARS-CoV-2 with high levels of sensitivity. The modified biosensor produces the test result within two minutes from a small nasal, throat or saliva specimen at the testing site with no central laboratory involvement. "Being able to test fast and accurate is important, but being able to deliver the test results anywhere, meaning at the side of a road, a remote lab, a patient's home or any kind of remoteness is really important for this point-of-care delivery." Bespoke in the True SenseWhat truly stands out in NanoDx's revolutionary system is its Internet of Things (IoT) compatibility. The system also supports WiFi and Bluetooth connections to help potentially trace infected individuals' movements. This supports multiple use cases. For example, a university with thousands of students can easily run rapid tests across the student population in classrooms, libraries, hotels, cafeterias and provide results in a couple of minutes. The rapid assessment can help identify the infected individuals, trace their movements in real-time, and warn the students who came into contact with infected people using a simple phone notification.NanoDx's unique diagnostic abilities have already grabbed the attention of airlines, amusement parks, large corporations, hospitals, and elderly care facilities. "NanoDx's fast and accurate testing along with the ability to track people in an effective way, while respecting their privacy, is exceptional in the market," Joshi adds. Route to Commercialization Currently, NanoDx is working tirelessly to apply for an Emergency Use Authorization (EUA) for their NanoDx System for SARS-CoV-2. They plan to get a Point-of-Care (POC) clearance on their system for a saliva test to allow expansion of their technology to clinics, urgent care facilities and remote testing sites. The company is also working on high volume manufacturing of affordable, reproducible, highly sensitive, and specific biosensors for many applications beyond COVID-19 and TBI. "We are looking to diagnose stroke, migraine, epilepsy, and cardiac issues with our solution as rapid test options are unavailable for these diseases at the moment. In such fields, remote testing would essentially result in cost savings along with effective and safe diagnosis," explains Joshi. In the meantime, NanoDx is ramping up its manufacturing capabilities to meet the massive demands of both COVID-19 and TBI testing. In summary, NanoDx aims to be a world leader in Nanosensor-Based, Real-Time, Point-of-Care Diagnostics for a wide variety of diseases. "Wherever there is a strong correlation between a biomarker and a disease, we aim to make the diagnosis process faster and more personalized," concludes Joshi. ""Our system is based on proprietary nanotechnology biosensors which rapidly detect and accurately measure biomarkers in a small patient specimen in just 2 minutes
< Page 9 | Page 11 >